Blood

Article	Citations
COVID-19 and its implications for thrombosis and anticoagulation	1722
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1046
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	955
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	887
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	875
Platelet gene expression and function in patients with COVID-19	718
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	568
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	534
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	520
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial	470
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	461
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	428
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	318
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	298
Venous thromboembolism in cancer patients: a population-based cohort study	286
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	284
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	277
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report	275
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients	244
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	239
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	238
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure	208
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	200
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era	197
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	194

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	189
Postdischarge thrombosis and hemorrhage in patients with COVID-19	181
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	176
Glucose-6-phosphate dehydrogenase deficiency	173
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial	169
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	162
Antibody-induced procoagulant platelets in severe COVID-19 infection	158
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	157
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI	157
NPM1-mutated acute myeloid leukemia: from bench to bedside	157
Postdischarge venous thromboembolism following hospital admission with COVID-19	155
Therapeutic options in VEXAS syndrome: insights from a retrospective series	151
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	150
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	148
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	146
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	145
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	141
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	139
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	138
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	136
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	136
Management of AL amyloidosis in 2020	135
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	134
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	134
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	131
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	127
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	121
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	121
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	121
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	120
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	120
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	119
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	119
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	119
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	115
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	115
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	114
Developmental trajectory of prehematopoietic stem cell formation from endothelium	114
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	114
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	112
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	112
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	112
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	109
Diamond-Blackfan anemia	109
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	109
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	106
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	105
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	105

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	105
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	102
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	101
Redefining outcomes in immune TTP: an international working group consensus report	99
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	98
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	98
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	98
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	98
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	97
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	95
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	95
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation	94
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	94
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	94
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	93
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR	93
How I treat relapsed acute lymphoblastic leukemia in the pediatric population	92
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	92
Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor	92
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	92
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	91
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	91
Real-world experience with caplacizumab in the management of acute TTP	91
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know	91
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma	90
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	90
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome	90
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma	89
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner	89
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	89
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis	88
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis	88
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	87
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report	87
Cancer immunoediting and immune dysregulation in multiple myeloma	87
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel	87
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CA	87
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	86
COVID-19 coagulopathy, thrombosis, and bleeding	86
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	86
Cold agglutinin disease revisited: a multinational, observational study of 232 patients	85
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke	85
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myel	84
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity	84
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia	84
BCL2 and MCL1 inhibitors for hematologic malignancies	84
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal	83
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group	83
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax	82
Platelets and extracellular vesicles and their cross talk with cancer	82
A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex–mediated DNA replication	82
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	82
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells	81
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an	80
Emicizumab for the treatment of acquired hemophilia A	80
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma	80
Leukemia secondary to myeloproliferative neoplasms	80
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity	79
Cancer spectrum and outcomes in the Mendelian short telomere syndromes	79
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies	79
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up	79
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma	78
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia	77
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis	77
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL	77
Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis	76
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	76
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?	75
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias	75
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma	75
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial	75
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML	75
Genetics of progression from MDS to secondary leukemia	75
Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production	75
Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis	74
ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic	73
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study	73
Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype	73
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation	73

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial	72
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia	72
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL	72
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues	72
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA	71
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy	71
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL	71
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)	70
Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease	69
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults	69
COVID-19 in patients with hematologic malignancy	69
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment	69
No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation	69
Genomic profiling for clinical decision making in lymphoid neoplasms	68
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas	68
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial	68
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals	68
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia	67
How I treat relapsed or refractory AML	67
How I treat paroxysmal nocturnal hemoglobinuria	67
Cytokines and costimulation in acute graft-versus-host disease	67
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL	67
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib	66
Vasculopathy in COVID-19	65
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma	65
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Trans	65
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers	65
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis	65
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax	65
Congenital dyserythropoietic anemias	65
Plasminogen: an enigmatic zymogen	65
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set	65
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition	64
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency	64
How I treat cold agglutinin disease	64
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL	64
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets	64
Mutational landscape of gray zone lymphoma	64
An intact gut microbiome protects genetically predisposed mice against leukemia	64
Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis	64
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients	64
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis	64
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with	63
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE	63
High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML	63
Primary central nervous system lymphoma	63
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial	63
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?	63
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial	63
Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations	62
TET2-mutant clonal hematopoiesis and risk of gout	62
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma	62
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemi	62
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma	62
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR	61
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial	61
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation	61
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial	60
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms	60
Lessons to learn from tumor-educated platelets	60
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial	60
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis	60
Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN	60
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity	60
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group	59
IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice	59
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria	59
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials	59
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant	59
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans	59
Germline TET2 loss of function causes childhood immunodeficiency and lymphoma	59
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications	59
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes	58
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients	58
CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles	58
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease	58
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors	58
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials	58
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity	58
Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies	58
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents	58
RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation	58
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition	58
Relationship between clone metrics and clinical outcome in clonal cytopenia	58
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity	58
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma	57
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL	57
Neutrophil HIF-1α stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle	56
A comprehensive transcriptome signature of murine hematopoietic stem cell aging	56
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC	56
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab	56
Aging-induced IL27Ra signaling impairs hematopoietic stem cells	56
Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project	56
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma	55
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs	55